QuidelOrtho
San Diego, California, United States · Biotechnology, Health Care, Health Diagnostics · 7,100 employees
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent in vitro diagnostics solutions that transform data into understanding and action for more people in more places every day. By offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, QuidelOrtho brings fast, accurat
Recent signals
- Apr 20, 2026: Acquired QuidelOrtho acquires LEX Diagnostics for $100 million
- Mar 24, 2026: QuidelOrtho Appoints Nathaniel Sisitsky as Chief Legal Officer
- Feb 11, 2026: SEC 8-K (2.02): On February 11, 2026, QuidelOrtho Corporation announced its financial results for the fourth quarter and full year ending December 28, 2025. This press release includes critical financial metrics that reflect the company's operational performance and strategic direction. The announcement coincides with a scheduled earnings conference call at 2:00 p.m. Pacific Time on the same day to provide further insights into the results and future outlook. This event is significant as it informs investors and stakeholders about the financial health of the company and helps guide future business decisions.
- Aug 19, 2025: QuidelOrtho Appoints Erich Wolff as Executive Vice President, Strategy & Corporate Development
- Aug 13, 2025: Launched QuidelOrtho Corporation has launched the Certified Analyzer Program to expand diagnostic testing access in underserved communities.
- Jul 14, 2025: QuidelOrtho and BÜHLMANN Laboratories AG Announce Partnership for fCAL and fPELA Turbo Assays on VITROS Systems.
- Sep 10, 2024: QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer
- May 02, 2024: QuidelOrtho Appoints Brian J. Blaser as President and CEO
See plans & pricing → Track QuidelOrtho’s funding, hiring, and signals — with verified contacts — on Fundz.